Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs BDMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 5 – 1 BDMD Matrix Metrics: DCTH 7 – 3 BDMD

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Baird Medical Investment Holdings Ltd Ordinary Share (BDMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BDMD carries 49.5/100 (HOLD) at $0.09 (0.7x Forward P/E, -58.5% operating margin).

  • Composite vs. Pillar Nuance: While BDMD currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -58.5% operating margin) and revenue trajectory (+70.7% vs. +24.6% YoY).
  • Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile BDMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs BDMD
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
BDMD NASDAQ
Baird Medical Investment Holdings Ltd Ordinary Share
Surgical & Medical Instruments & Apparatus
$0.09
-2.54% 1D
Market Cap $3.4M
TTM Revenue $24M
Forward P/E 0.7x
Beta / 30D Vol 0.20β · 302% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 60.0 Fund 58.0 Flow 50.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.8%), weak momentum, RSI 22
RSI-14: 21.6 · SMA20: $0.22 · SMA50: $0.59

6-Pillar Scorecard Institutional Category Breakdown (DCTH 5 – 1 BDMD)

Columns: Metric · DCTH · BDMD
1. Valuation Multiples BDMD
Forward P/E N/M 0.7x
Trailing P/E 133.6x 0.7x
PEG Ratio 1.60x N/M
EV / Revenue 6.3x 0.1x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +24.6%
Earnings Growth (YoY) +750.0% -0.3%
TTM Revenue (USD) $110M $24M
Market Cap $743.8M $3.4M
3. Profitability & Quality DCTH
Gross Margin 87.6% 85.6%
Operating Margin 5.2% -58.5%
Net Profit Margin 6.0% -65.1%
Return on Equity (ROE) 5.4% -46.0%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$13M EBITDA
Cash Flow Margin 18.3% -54.4% EBITDA Mgn
Net Cash / Leverage $53M Net Cash $1.09 Book/Sh · -46.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 109.3% (43rd %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (7) vs BDMD (3)
Institutional Metric DCTH BDMD Criterion Row Edge
Market Capitalization
Scale
$743.8M $3.4M Larger Scale DCTH
Trailing P/E Ratio
Valuation
133.6x 0.7x Lower Multiple BDMD
Forward P/E Ratio
Valuation
N/M 0.7x Lower Multiple BDMD
Revenue Growth (YoY)
Growth
+70.7% +24.6% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -58.5% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -65.1% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -46.0% Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 0% ($0–$4) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.20β · 302% Vol Lower Realized Risk DCTH
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 49.5 / 100 (HOLD) Higher Composite BDMD
Trailing 12M Revenue (USD)
Operating Scale
$110M $24M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 85.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$13M EBITDA ($1.09 Book/Sh · -46.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +124.19 pp
DCTH: +39.77% · BDMD: -84.42%
3M Horizon DCTH +108.64 pp
DCTH: +16.73% · BDMD: -91.91%
6M Horizon DCTH +172.08 pp
DCTH: +77.46% · BDMD: -94.62%
1Y Horizon DCTH +221.68 pp
DCTH: +128.57% · BDMD: -93.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCTH vs BDMD. Trailing 12-month operating profitability (DCTH 5.2% vs BDMD -58.5%) and valuation multiples (DCTH N/M vs BDMD 0.7x Forward P/E) are benchmarked directly in Pillar 4 below.

DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M
BDMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$24M
Gross Margin85.6%
Op. Margin-58.5%
ROE / Fwd P/E-46.0% · 0.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDMD BREAKDOWN
176d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BDMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
BDMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.4M market capitalization and -58.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs BDMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Baird Medical Investment Holdings Ltd Ordinary Share (BDMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BDMD carries 49.5/100 (HOLD) at $0.09 (0.7x Forward P/E, -58.5% operating margin). Composite vs. Pillar Nuance: While BDMD currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -58.5% operating margin) and revenue trajectory (+70.7% vs. +24.6% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile BDMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with BDMD at +24.6% YoY revenue growth and -0.3% YoY earnings growth on $24M TTM revenue (85.6% gross margin, -58.5% operating margin). On trailing 12-month operating scale, DCTH generates $110M in USD-normalized revenue versus $24M for BDMD. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BDMD.

BDMD screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas BDMD trades at 0.7x Forward P/E, 0.7x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-54.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus BDMD (-46.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, BDMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.20β · 302% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.